<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The proto-oncogene C-KIT encodes a tyrosine kinase receptor that is expressed on mast cells and haematopoietic stem cells and can show <z:hpo ids='HP_0001428'>somatic mutations</z:hpo> in patients with <z:hpo ids='HP_0100495'>mastocytosis</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Only scattered information is available about mutations in C-KIT in patients with other myeloid <z:hpo ids='HP_0002664'>neoplasms</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Moreover, the prevalence of mutations in C-KIT in bone marrow specimens of individuals with systemic <z:hpo ids='HP_0100495'>mastocytosis</z:hpo> is largely unknown </plain></SENT>
<SENT sid="3" pm="."><plain>Using sequence analysis, we have screened cDNAs of the C-KIT domain encompassing codon 510-626 and codon 763-858 in bone marrow (BM) mononuclear cells (MNCs) of patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (n = 28) and patients with systemic <z:hpo ids='HP_0100495'>mastocytosis</z:hpo> (n = 12) for the presence of mutations </plain></SENT>
<SENT sid="4" pm="."><plain>Furthermore, restriction fragment length polymorphism analysis was applied for identification of the C-KIT 2468A--&gt;T and the C-KIT 1700T--&gt;G mutation, as well as the C-KIT 1642A--&gt;C polymorphism </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> 11 patients with systemic indolent <z:hpo ids='HP_0100495'>mastocytosis</z:hpo> tested positive for C-KIT 2468A--&gt;T </plain></SENT>
<SENT sid="6" pm="."><plain>In contrast, no mutation was identified in the case of aggressive <z:hpo ids='HP_0100495'>mastocytosis</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Among patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo>, no patient showed a <z:hpo ids='HP_0001428'>somatic mutation</z:hpo> in C-KIT </plain></SENT>
<SENT sid="8" pm="."><plain>The allele frequency for C-KIT 1642A--&gt;C among the entire patient population was 0.038 and was 0.125 among age- and sex-matched healthy controls </plain></SENT>
<SENT sid="9" pm="."><plain>Our data demonstrate that <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> without histological or cytological evidence of <z:hpo ids='HP_0100495'>mastocytosis</z:hpo> do not exhibit <z:hpo ids='HP_0001428'>somatic mutations</z:hpo> in exons 10, 11, 12, 16, 17 and 18 of C-KIT </plain></SENT>
<SENT sid="10" pm="."><plain>In contrast, BM MNCs of patients with systemic indolent <z:hpo ids='HP_0100495'>mastocytosis</z:hpo> were <z:hpo ids='HP_0000001'>all</z:hpo> positive for C-KIT 2468A--&gt;T and negative for additional mutations in these exons </plain></SENT>
<SENT sid="11" pm="."><plain>The C-KIT 1642A--&gt;C polymorphism is not associated with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> or systemic <z:hpo ids='HP_0100495'>mastocytosis</z:hpo> </plain></SENT>
</text></document>